Plain-English translation of NCT06528314 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if it can help people with compensated cirrhosis—advanced liver scarring—caused by metabolic dysfunction-associated fatty liver disease. About 2,150 people will participate, and half will receive the medication while half receive a placebo (a dummy pill with no active drug). Researchers want to understand whether this treatment is safe and effective for slowing or improving liver disease at this advanced stage.
Advanced liver scarring from metabolic dysfunction is a serious condition, and there are currently limited treatment options available. This trial exists to see whether this medication could offer a new way to help patients whose livers are already severely damaged but not yet in complete failure.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the medication or a placebo, and neither you nor your doctor will know which one you're getting (this is called a double-blind study). You will visit the study clinic multiple times for check-ups, blood tests, and possibly imaging scans to monitor your liver health and how your body responds to the treatment. The trial will track your safety and whether the medication helps improve your liver condition over time.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States